Hudson Bay Capital Management LP Raises Stock Position in Cytokinetics, Incorporated $CYTK

Hudson Bay Capital Management LP lifted its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 15.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 182,131 shares of the biopharmaceutical company’s stock after acquiring an additional 24,345 shares during the quarter. Hudson Bay Capital Management LP’s holdings in Cytokinetics were worth $10,010,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the stock. Millennium Management LLC raised its position in Cytokinetics by 361.9% in the first quarter. Millennium Management LLC now owns 287,901 shares of the biopharmaceutical company’s stock valued at $11,571,000 after purchasing an additional 225,576 shares during the period. Envestnet Asset Management Inc. boosted its position in shares of Cytokinetics by 21.2% in the second quarter. Envestnet Asset Management Inc. now owns 29,467 shares of the biopharmaceutical company’s stock worth $974,000 after buying an additional 5,146 shares during the period. Geode Capital Management LLC boosted its position in shares of Cytokinetics by 1.9% in the second quarter. Geode Capital Management LLC now owns 2,994,445 shares of the biopharmaceutical company’s stock worth $98,948,000 after buying an additional 56,961 shares during the period. Police & Firemen s Retirement System of New Jersey grew its stake in shares of Cytokinetics by 5.3% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 26,231 shares of the biopharmaceutical company’s stock valued at $867,000 after buying an additional 1,320 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its stake in shares of Cytokinetics by 8.8% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 30,684 shares of the biopharmaceutical company’s stock valued at $1,014,000 after buying an additional 2,474 shares in the last quarter.

Cytokinetics Stock Performance

NASDAQ:CYTK opened at $62.95 on Friday. The company has a market capitalization of $7.75 billion, a price-to-earnings ratio of -9.64 and a beta of 0.56. Cytokinetics, Incorporated has a one year low of $29.31 and a one year high of $70.98. The stock has a 50-day simple moving average of $63.79 and a 200 day simple moving average of $60.95.

Cytokinetics (NASDAQ:CYTK) last released its earnings results on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) EPS for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.02). The business had revenue of $17.76 million during the quarter, compared to the consensus estimate of $8.02 million. The firm’s revenue was up 4.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.26) earnings per share. On average, equities research analysts forecast that Cytokinetics, Incorporated will post -5.24 EPS for the current fiscal year.

Cytokinetics News Summary

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Mizuho raised its price target to $100 and kept an “outperform” rating, implying meaningful upside vs. the current share price — a catalyst for momentum buying. Mizuho raises target to $100
• Positive Sentiment: JPMorgan raised its target to $75 and maintained an overweight stance, adding institutional analyst support that can attract fund flows. JPMorgan raises target to $75
• Positive Sentiment: Large institutional holders (e.g., Vanguard, State Street) have been increasing positions, which supports longer‑term demand and underpins current price strength. Institutional holdings update
• Neutral Sentiment: Cytokinetics granted inducement awards (8,628 options and 5,719 RSUs) to five new hires under Nasdaq Rule 5635(c)(4); standard hiring comp — modest future dilution but intended to secure talent. Inducement grants
• Neutral Sentiment: Latest quarter showed a slight EPS miss but a revenue beat — mixed fundamentals that appear secondary to the recent analyst target moves in driving sentiment. Earnings recap
• Neutral Sentiment: Reported short‑interest data for March appears inconsistent/empty and is not a clear near‑term signal (days‑to‑cover shown as 0.0), so treat that item as noise until clarified by exchanges.
• Negative Sentiment: Significant insider selling: CEO Robert Blum sold ~36,601 shares (~$2.27M) and multiple EVPs sold large blocks across March. Large, clustered insider disposals can create short‑term selling pressure or be interpreted as diversification — worth monitoring for follow‑through. Insider selling details

Insider Activity

In other Cytokinetics news, EVP Sung Lee sold 4,935 shares of Cytokinetics stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $62.15, for a total value of $306,710.25. Following the completion of the transaction, the executive vice president owned 87,127 shares of the company’s stock, valued at $5,414,943.05. The trade was a 5.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Wendell Wierenga sold 20,000 shares of the business’s stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $66.14, for a total transaction of $1,322,800.00. Following the sale, the director owned 32,444 shares of the company’s stock, valued at approximately $2,145,846.16. The trade was a 38.14% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 159,663 shares of company stock valued at $9,944,292 over the last three months. 2.70% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts recently commented on CYTK shares. Leerink Partners reissued an “outperform” rating on shares of Cytokinetics in a research report on Tuesday, March 10th. Citigroup reaffirmed a “market outperform” rating on shares of Cytokinetics in a research report on Monday, December 22nd. Truist Financial boosted their target price on shares of Cytokinetics from $84.00 to $92.00 and gave the stock a “buy” rating in a research report on Tuesday, February 3rd. Needham & Company LLC upped their target price on shares of Cytokinetics from $84.00 to $85.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Finally, Morgan Stanley set a $90.00 price target on shares of Cytokinetics in a report on Thursday, January 8th. Seventeen analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $89.89.

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.